Skip to content

Guidelines

TL;DR — Contemporary bipolar-disorder guidelines agree that treatment must be phase-specific, that antidepressant monotherapy is unsafe in bipolar I disorder, that maintenance planning begins during acute care, and that suicide, physical health, reproductive risk and adherence require explicit monitoring (Yatham 2018, PMID 29536616; Malhi 2021, PMID 33353391; Ostacher 2025, PMID 39832345). They disagree more about sequencing than about the evidence base: lithium, valproate/divalproex and several second-generation antipsychotics recur across acute-mania algorithms, whereas bipolar-depression rankings vary more substantially (Parker 2017, PMID 28260229; Park 2024, PMID 38586960). CANMAT/ISBD 2018 remains the most comprehensive widely used international document, supplemented by a 2023 evidence update; NICE CG185 was last updated in September 2025, VA/DoD issued a US federal guideline in 2023, and the Indian Psychiatric Society replaced its 2017 adult guideline (Shah 2017, PMID 28216785) with a 2025 update published in 2026 (Menon 2026, PMID 41694044). A live 2026-08-30 search of the retrieved guideline texts found no routine diagnostic or treatment-selection rule based on a molecular marker, polygenic score or passive-sensing output.

Scope and method

Guidelines compress heterogeneous randomized trials, observational safety data and expert judgment into sequences. Their rankings cannot be read as interchangeable: documents differ in whether they rank monotherapy before combinations, how they penalize metabolic or reproductive harm, which drugs are locally licensed, and whether “first line” means evidence strength, clinical preference, or both (Parker 2017, PMID 28260229; Park 2024, PMID 38586960).

Major guideline families

Body / document Region Year / current status Scope Verified source
CANMAT/ISBD Canada / international 2018; evidence update 2023 Acute mania, bipolar depression, maintenance, special populations Yatham 2018, PMID 29536616; Keramatian 2023, PMID 38695002
NICE CG185 England and Wales 2014; updated 2 Sep 2025 Recognition, acute and long-term treatment, children and adults NICE, https://www.nice.org.uk/guidance/cg185, accessed 2026-08-30
VA/DoD United States 2023 Primary/specialty-care algorithms for adults Ostacher 2025, PMID 39832345; VA/DoD, https://healthquality.va.gov/HEALTHQUALITY/guidelines/mh/bd/index.asp, accessed 2026-08-30
APA United States 2002; Guideline Watch 2005; explicitly not current Full treatment guideline plus evidence watch APA, https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar-1410197656063.pdf, accessed 2026-08-30
BAP United Kingdom 2016, revised third edition Evidence-based biological and psychosocial treatment Goodwin 2016, PMID 26979387
RANZCP Australia / New Zealand 2020; society now labels it >5 years old and not current Mood disorders including bipolar disorder Malhi 2021, PMID 33353391; RANZCP, https://www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/mood-disorders-cpg, accessed 2026-08-30
CINP-BD International 2017 Evidence grading, algorithm and clinical guidance Fountoulakis 2017, PMID 27815414; PMID 27816941; PMID 27941079
WFSBP International 2013 maintenance; 2018 mixed states Biological treatment Grunze 2013, PMID 23480132; Grunze 2018, PMID 29098925
JSMD Japan 2023 guideline; English publication 2024 Pharmacotherapy, psychosocial support, perinatal care, monitoring Kato 2024, PMID 39194164
Chinese guideline summary China 2018 update Assessment and management Wang 2018, PMID 29604156
Indian Psychiatric Society India 2025 adult update, published 2026; 2019 children/adolescents Diagnosis and phase-specific management Menon 2026, PMID 41694044; Gautam 2019, PMID 30745704
Taiwan consensus Taiwan 2022 update, published 2023 Acute, maintenance and mixed phases Cheng 2023, PMID 36724568
KMAP-BP South Korea Five editions through 2018; longitudinal comparison 2020 Expert medication algorithm Jon 2020, PMID 32202033
AWMF S3 / BipolarLiving Germany Prior guideline validity ended 31 May 2026; version 2.1 update registered May 2025 Diagnosis and treatment update project AWMF, https://www.awmf.org/aktuelles/awmf-aktuell/diagnostik-und-therapie-bipolarer-stoerungen-bipolarliving, accessed 2026-08-30

Cross-guideline consensus

Decision point Broad consensus Important qualification
Acute mania Use an antimanic mood stabilizer and/or an evidence-supported antipsychotic; combinations are reasonable when severity, psychosis or agitation requires faster control (Yatham 2018, PMID 29536616; Goodwin 2016, PMID 26979387) Local approval and tolerability alter rankings; mixed presentations have a separate WFSBP document (Grunze 2018, PMID 29098925)
Bipolar depression Use treatments with bipolar-depression evidence rather than extrapolating directly from unipolar depression (Keramatian 2023, PMID 38695002; Park 2024, PMID 38586960) The largest disagreements are the order of quetiapine, lurasidone, lithium, lamotrigine and newer antipsychotics
Antidepressants Avoid antidepressant monotherapy in bipolar I; if used, combine with an antimanic agent and monitor switch or cycle acceleration (Yatham 2018, PMID 29536616; Goodwin 2016, PMID 26979387) Guideline language varies from restricted adjunctive use to stronger discouragement, especially with mixed features
Maintenance Choose according to prior response and polarity; lithium has the most persistent cross-guideline role (Grunze 2013, PMID 23480132; Yatham 2018, PMID 29536616) Acute efficacy does not guarantee prevention of both manic and depressive recurrence
Psychosocial care Psychoeducation, relapse-signature work, family involvement and structured psychotherapy complement medication (Malhi 2021, PMID 33353391; Yatham 2018, PMID 29536616) Availability and fidelity are major implementation constraints
Suicide Assess directly and repeatedly; integrate crisis and means-safety planning rather than relying on medication alone (Ostacher 2025, PMID 39832345) Lithium's population-level signal does not make it a stand-alone acute suicide-prevention intervention
Physical health Monitor weight, blood pressure, glucose/lipids and drug-specific renal, thyroid, hepatic or hematologic risks (Yatham 2018, PMID 29536616; NICE CG185, accessed 2026-08-30) Monitoring frequency differs with drug, age, comorbidity and local shared-care systems
Reproductive health Discuss contraception, pregnancy intentions and fetal/neonatal risks before exposure to high-risk drugs (ACOG 2023, PMID 37486661) Valproate restrictions have tightened asynchronously across countries

Where recommendations diverge

Bipolar depression

Comparative reviews find lower consensus for bipolar depression than for mania. The disagreement is not evidence-free: it reflects different dates, network-meta-analytic inputs, tolerability penalties, local formularies and willingness to recommend adjunctive antidepressants (Parker 2017, PMID 28260229; Park 2024, PMID 38586960). A page should therefore report the source guideline and year rather than write “guidelines recommend” as though there were one global sequence.

Maintenance and polarity

WFSBP's maintenance document grades long-term evidence separately from acute response, while CANMAT/ISBD integrates prior acute response, predominant polarity and adverse effects (Grunze 2013, PMID 23480132; Yatham 2018, PMID 29536616). CINP publishes method, evidence grading and clinical algorithm as three linked papers; its sequence should not be reduced to the clinical paper alone (Fountoulakis 2017, PMID 27815414; PMID 27816941; PMID 27941079).

Guideline families also evolve through summaries and position papers: CANMAT's development history documents its iterative architecture, and the RANZCP bipolar summary condenses the longer mood-disorders guideline rather than replacing it (Yatham 2013, PMID 23339676; Malhi 2018, PMID 29540132).

Mixed presentations and rapid cycling

Mixed states expose a classification problem: studies used older “mixed episode” definitions as well as DSM-5 mixed-features specifiers. WFSBP therefore devoted a separate guideline to acute and long-term treatment of mixed states (Grunze 2018, PMID 29098925). Taiwan's 2022 consensus also separates mixed phases, whereas NICE states that rapid cycling should receive the same interventions because it found no strong evidence for a different pathway (Cheng 2023, PMID 36724568; NICE CG185, accessed 2026-08-30).

Children and adolescents

Pediatric guidance is thinner and more cautious because adult efficacy cannot be assumed to transfer cleanly. The older international pediatric pharmacotherapy guideline, India's child/adolescent guideline and NICE all emphasize longitudinal diagnosis, developmental context and family involvement (Kowatch 2005, PMID 15725966; Gautam 2019, PMID 30745704; NICE CG185, accessed 2026-08-30).

Pregnancy and postpartum

The ACOG 2023 mental-health treatment guideline includes bipolar disorder within pregnancy and postpartum prescribing decisions (ACOG 2023, PMID 37486661). This is a safety domain in which local regulatory changes can make older general bipolar guidelines materially stale; reproductive recommendations require checking current regulator language as well as the psychiatric guideline.

Monitoring matrix

Exposure / domain Baseline Ongoing focus Escalation trigger
Lithium Renal and thyroid function, calcium, interacting medicines, pregnancy context Serum concentration plus renal/thyroid/calcium surveillance Gastrointestinal and neurologic toxicity, dehydration, acute kidney injury, interacting drug initiation (Yatham 2018, PMID 29536616)
Valproate/divalproex Reproductive-risk restrictions, liver and hematologic assessment Weight/metabolic, hepatic and hematologic effects Pregnancy or pregnancy planning; hepatic or bleeding concerns (ACOG 2023, PMID 37486661)
Antipsychotics Weight/BMI, blood pressure, glucose or HbA1c, lipids; ECG when indicated Weight trajectory, metabolic profile, movement effects Rapid weight gain, hyperglycemia, dyslipidemia, severe rigidity/fever
Lamotrigine Concomitant medicines and titration plan Rash education during titration New rash or systemic symptoms; urgent assessment rather than self-rechallenge
Antidepressant adjunct Current/past mania, mixed features, rapid cycling Sleep need, activation, agitation, impulsivity Emerging hypomania/mania or mixed symptoms
All phases Suicide/self-harm, substance use, psychosis, violence/exploitation, ability to care for self Crisis plan, adherence, sleep and function Immediate danger, severe mania/depression, psychosis or inability to maintain safety (NICE CG185, accessed 2026-08-30)

Implementation and evidence gaps

The existence of multiple algorithms does not guarantee concordant practice. Studies and commentaries have described gaps between bipolar guideline recommendations and clinical care, while comparative analyses show that disagreement is concentrated in sequence and combination choices (Giese 2009, PMID 19884231; Parker 2017, PMID 28260229). RANZCP now marks its 2020 document as no longer current, and APA's hosted 2002 guideline explicitly says it cannot be assumed current; both should remain in a registry for provenance but not be presented as contemporary standards (RANZCP and APA official pages, accessed 2026-08-30). The German AWMF register documents a version 2.1 update project, but the prior guideline's formal validity ended on 31 May 2026; the project registration is not a completed replacement (AWMF, accessed 2026-08-30).

The 2023 CANMAT/ISBD update is a summary and evidence update, not a complete replacement for every detailed 2018 section (Keramatian 2023, PMID 38695002). Similarly, the published VA/DoD synopsis is a compact route into the 2023 full guideline, not a substitute for its evidence tables (Ostacher 2025, PMID 39832345).

Special-purpose guidance

General bipolar guidelines cannot carry every high-risk scenario. Three narrower documents are useful adjuncts:

Topic Document Use and boundary
Emergency agitation International expert consensus Structures assessment, verbal de-escalation and medication routes across psychiatric agitation; it is not bipolar-specific efficacy guidance (Garriga 2016, PMID 26912127)
Nutraceuticals / phytoceuticals WFSBP/CANMAT taskforce Grades adjunctive evidence across psychiatric disorders; should not displace established phase-specific treatment (Sarris 2022, PMID 35311615)
VA/DoD implementation summary American Family Physician synopsis Provides primary-care-facing interpretation of the 2023 federal guideline; use the full CPG for evidence strength and rationale (Arnold 2024, PMID 38905567)

Guideline provenance and watch list

Document Provenance state at 2026-08-30 Next check
CANMAT/ISBD 2018 Current base document with 2023 evidence update Full replacement or additional focused updates
NICE CG185 Live; page reports update 2 Sep 2025 New surveillance decision, especially valproate restrictions
VA/DoD 2023 Current US federal CPG Evidence review or amendment
APA 2002 / 2005 Watch Historical; hosted PDF explicitly disclaims currency New APA bipolar guideline
BAP 2016 Published third edition; no newer bipolar edition verified Revision incorporating newer antipsychotics
RANZCP 2020 Society marks as no longer current Replacement Australian/New Zealand CPG
JSMD 2023 Current society guideline; English paper 2024 Drug-approval and evidence updates
WFSBP maintenance 2013 Topic-specific but old Replacement long-term guideline
Indian Psychiatric Society 2025 update Current adult update, published 2026 Implementation evidence and future revisions
German AWMF S3 / BipolarLiving Prior document expired; version 2.1 update registered Completed updated guideline

This provenance matters clinically: “major guideline” describes influence, not currency. Historical documents remain valuable for tracing why practice changed, but an explicitly retired or stale document should never silently govern a current recommendation.

Mixed presentations expose the evidence hierarchy

The CANMAT/ISBD mixed-presentations update found no agent meeting its first-line threshold for DSM-5 manic or depressive episodes with mixed features. For mania with mixed features, asenapine, cariprazine, divalproex and aripiprazole were second line; for depression with mixed features, cariprazine and lurasidone were second line. By contrast, under the older DSM-IV mixed-episode construct, asenapine and aripiprazole were first line; maintenance after DSM-5 mixed presentations fell to third-line expert opinion (Yatham 2021, PMID 34599629). Recommendation rank therefore changes with the phenotype being graded.

Guideline disagreements also arise from evidence synthesis, not just values. A methodological critique argued that NICE psychological-treatment meta-analyses contained flaws serious enough to challenge the recommendations drawn from them (Jauhar 2016, PMID 26853311). That critique does not prove psychotherapy ineffective; it requires readers to inspect comparator choice, outcome pooling and trial quality behind a nominal recommendation.

The British Association for Psychopharmacology explicitly rated evidence strength and paired recommendations with a selective qualitative review, covering acute episodes, relapse prevention and stopping treatment (Goodwin 2009, PMID 19329543). The historical 2007 CANMAT update classified quetiapine monotherapy as first line for bipolar depression while retaining lithium, lamotrigine and selected combinations, showing how “first line” is version-specific rather than timeless (Yatham 2006, PMID 17156158).

ACOG uses a modified GRADE evidence-to-decision framework and explicitly labels ungraded good-practice points where perinatal evidence is inadequate (ACOG 2023, PMID 37486660). Consequently, a strong safety-oriented perinatal statement and a high-certainty efficacy recommendation are not interchangeable even when both appear in a guideline.

Open questions

  • Can one transparent living-guideline method reconcile the large bipolar-depression sequencing differences identified in international comparisons (Parker 2017, PMID 28260229; Park 2024, PMID 38586960)?
  • Which recommendations change outcomes when implemented, rather than merely changing prescribing concordance (Giese 2009, PMID 19884231)?
  • How should guidelines incorporate patient-important outcomes such as cognition, sexual function and ability to work alongside symptom scores?
  • What evidence threshold should be required before digital relapse prediction enters a guideline algorithm?
  • Can reproductive-risk policies be harmonized without obscuring differences in regulation, access and patient preference (ACOG 2023, PMID 37486661)?

References

  1. Yatham LN, et al. Canadian Network for Mood and Anxiety Treatments and International Society for Bipolar Disorders 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97-170. PMID 29536616
  2. Keramatian K, et al. The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus. 2023;21:344-353. PMID 38695002
  3. Malhi GS, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55:7-117. PMID 33353391
  4. Ostacher MJ, et al. Synopsis of the 2023 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline for the Management of Bipolar Disorder. J Clin Psychiatry. 2025;86:24cs15546. PMID 39832345
  5. Goodwin GM, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30:495-553. PMID 26979387
  6. Fountoulakis KN, et al. CINP Treatment Guidelines for Bipolar Disorder in Adults, Part 1: Background and Methods. Int J Neuropsychopharmacol. 2017;20:98-120. PMID 27815414
  7. Fountoulakis KN, et al. CINP Treatment Guidelines for Bipolar Disorder in Adults, Part 2: Review, Grading of Evidence, and Algorithm. Int J Neuropsychopharmacol. 2017;20:121-179. PMID 27816941
  8. Fountoulakis KN, et al. CINP Treatment Guidelines for Bipolar Disorder in Adults, Part 3: Clinical Guidelines. Int J Neuropsychopharmacol. 2017;20:180-195. PMID 27941079
  9. Grunze H, et al. WFSBP guidelines: update 2012 on long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14:154-219. PMID 23480132
  10. Grunze H, et al. WFSBP Guidelines: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry. 2018;19:2-58. PMID 29098925
  11. Kato T, et al. Practice Guidelines for Bipolar Disorder by the Japanese Society of Mood Disorders. Psychiatry Clin Neurosci. 2024;78:633-645. PMID 39194164
  12. Wang Z, et al. Assessment and management of bipolar disorder: Principal summary of updated Chinese guidelines. Bipolar Disord. 2018;20:289-292. PMID 29604156
  13. Shah N, et al. Clinical Practice Guidelines for Management of Bipolar Disorder. Indian J Psychiatry. 2017;59:S51-S66. PMID 28216785
  14. Gautam S, et al. Clinical Practice Guidelines for Bipolar Affective Disorder in Children and Adolescents. Indian J Psychiatry. 2019;61:S294-S305. PMID 30745704
  15. Cheng CM, et al. Taiwan consensus on biological treatment of bipolar disorder: the 2022 update. Asian J Psychiatr. 2023;82:103480. PMID 36724568
  16. Jon DI, et al. Korean Medication Algorithm Project for Bipolar Disorder: changes over 16 years and five editions. Bipolar Disord. 2020;22:461-471. PMID 32202033
  17. Parker GB, et al. Is there consensus across international evidence-based guidelines for the management of bipolar disorder? Acta Psychiatr Scand. 2017;135:515-526. PMID 28260229
  18. Park JH, et al. Global perspectives on bipolar disorder treatment: comparative analysis of international guidelines. BJPsych Open. 2024;10:e75. PMID 38586960
  19. American College of Obstetricians and Gynecologists. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: Clinical Practice Guideline No. 5. Obstet Gynecol. 2023;141:1262-1288. PMID 37486661
  20. Kowatch RA, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:213-235. PMID 15725966
  21. Giese AA, et al. Closing the gap between guidelines for bipolar disorder treatment and clinical practice. Am J Psychiatry. 2009;166:1205-1206. PMID 19884231
  22. Yatham LN. The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disord. 2013;15:58-60. PMID 23339676
  23. Malhi GS, et al. RANZCP clinical practice guidelines for mood disorders: bipolar disorder summary. Med J Aust. 2018;208:219-225. PMID 29540132
  24. Garriga M, et al. Assessment and management of agitation in psychiatry: Expert consensus. World J Biol Psychiatry. 2016;17:86-128. PMID 26912127
  25. Sarris J, et al. WFSBP and CANMAT clinician guidelines for psychiatric disorders with nutraceuticals and phytoceuticals. World J Biol Psychiatry. 2022;23:424-455. PMID 35311615
  26. Arnold MJ. Management of Bipolar Disorder: Guidelines From the VA/DoD. Am Fam Physician. 2024;109:585-587. PMID 38905567
  27. Menon V, et al. Clinical practice guidelines for the management of bipolar disorder: 2025 update. Indian J Psychiatry. 2026;68:8-43. PMID 41694044
  28. Yatham LN, et al. CANMAT and ISBD recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disord. 2021;23:767–788. PMID 34599629
  29. Jauhar S, et al. NICE guidance on psychological treatments for bipolar disorder: searching for the evidence. Lancet Psychiatry. 2016;3:386–388. PMID 26853311
  30. Goodwin GM, et al. Evidence-based guidelines for treating bipolar disorder: revised second edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23:346–388. PMID 19329543
  31. American College of Obstetricians and Gynecologists. Screening and diagnosis of mental health conditions during pregnancy and postpartum: Clinical Practice Guideline No. 4. Obstet Gynecol. 2023;141:1232–1261. PMID 37486660
  32. Yatham LN, et al. CANMAT guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8:721–739. PMID 17156158